In the last 18 months NHS Protect has commenced three investigations into directors of National Health Service trusts. All three investigations are ongoing and further information cannot be given at this time.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} , "dateOfAnswer" : {"_value" : "2015-10-29", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2015-10-29T17:29:11.887Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2015-10-26", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "NHS Protect"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, how many investigation NHS Protect have commenced into directors of NHS Trusts (a) nationally and (b) in Yorkshire in the last 18 months; and how many of those investigations are ongoing.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1533", "label" : {"_value" : "Biography information for Dame Diana Johnson"} } , "tablingMemberConstituency" : {"_value" : "Kingston upon Hull North"} , "tablingMemberPrinted" : [{"_value" : "Diana Johnson"} ], "uin" : "13485"} , {"_about" : "http://data.parliament.uk/resources/423804", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/423804/answer", "answerText" : {"_value" : "
This information is not held centrally and could only be obtained at disproportionate cost.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2015-10-29", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2015-10-29T17:30:23.23Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-10-26", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "NHS Protect"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what the average time is for NHS Protect to complete an investigation.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1533", "label" : {"_value" : "Biography information for Dame Diana Johnson"}
}
, "tablingMemberConstituency" : {"_value" : "Kingston upon Hull North"}
, "tablingMemberPrinted" : [{"_value" : "Diana Johnson"}
], "uin" : "13484"}
, {"_about" : "http://data.parliament.uk/resources/423864", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/423864/answer", "answerText" : {"_value" : "
Information is not collected centrally on the number of people prescribed medicines or the medical condition being treated.<\/p>
Some data is available for the administration of vedolizumab however this data does not correspond to patient numbers nor can it be linked to the treatment of specific diseases. Some information on cost is also available but this is the cost of the medicines at NHS list price and not necessarily the price that hospitals paid.<\/p>
In guidance published in August 2015, the National Institute for Health and Care Excellence (NICE) advised that vedolizumab is the recommended treatment for adults with moderate to severe Crohn\u2019s disease if a type of treatment called a tumour necrosis factor alpha inhibitor is not suitable or has not worked well enough. NICE also recommend vedolizumab as a possible treatment for adults with moderate to severe ulcerative colitis in separate guidance published on 5 June 2015.<\/p>
In both cases, people should be able to have vedolizumab until it stops working, or surgery is needed, or for 12 months after starting it, whichever is shorter. Their condition should be assessed 12 months after they started taking vedolizumab. If they still have symptoms but it is clear that the treatment is helping, they can continue to have the drug. If they no longer have symptoms, treatment can be stopped, and later restarted if their symptoms return. Drugs recommended by NICE should be available on the NHS within three months of the technology appraisal guidance being issued.<\/p>
NICE has set out best practice in the diagnosis, treatment care and support of patients with Crohn\u2019s diseases and ulcerative colitis in its guidance Crohn\u2019s Disease Management in Adults, Children and Young People<\/em> in October 2012, and Ulcerative Colitis<\/em> Management in Adults, Children and Young People<\/em> , published in June 2013. Treatment for both Crohn\u2019s disease and ulcerative colitis is largely directed at symptom relief to improve quality of life, rather than cure. Management options include drug therapy, dietary and lifestyle advice and, in severe or chronic active disease, surgery.<\/p> Information is not collected centrally on the number of people prescribed medicines or the medical condition being treated.<\/p> Some data is available for the administration of vedolizumab however this data does not correspond to patient numbers nor can it be linked to the treatment of specific diseases. Some information on cost is also available but this is the cost of the medicines at NHS list price and not necessarily the price that hospitals paid.<\/p> In guidance published in August 2015, the National Institute for Health and Care Excellence (NICE) advised that vedolizumab is the recommended treatment for adults with moderate to severe Crohn\u2019s disease if a type of treatment called a tumour necrosis factor alpha inhibitor is not suitable or has not worked well enough. NICE also recommend vedolizumab as a possible treatment for adults with moderate to severe ulcerative colitis in separate guidance published on 5 June 2015.<\/p> In both cases, people should be able to have vedolizumab until it stops working, or surgery is needed, or for 12 months after starting it, whichever is shorter. Their condition should be assessed 12 months after they started taking vedolizumab. If they still have symptoms but it is clear that the treatment is helping, they can continue to have the drug. If they no longer have symptoms, treatment can be stopped, and later restarted if their symptoms return. Drugs recommended by NICE should be available on the NHS within three months of the technology appraisal guidance being issued.<\/p> NICE has set out best practice in the diagnosis, treatment care and support of patients with Crohn\u2019s diseases and ulcerative colitis in its guidance Crohn\u2019s Disease Management in Adults, Children and Young People<\/em> in October 2012, and Ulcerative Colitis<\/em> Management in Adults, Children and Young People<\/em> , published in June 2013. Treatment for both Crohn\u2019s disease and ulcerative colitis is largely directed at symptom relief to improve quality of life, rather than cure. Management options include drug therapy, dietary and lifestyle advice and, in severe or chronic active disease, surgery.<\/p> Information is not collected centrally on the number of people prescribed medicines or the medical condition being treated.<\/p> Some data is available for the administration of vedolizumab however this data does not correspond to patient numbers nor can it be linked to the treatment of specific diseases. Some information on cost is also available but this is the cost of the medicines at NHS list price and not necessarily the price that hospitals paid.<\/p> In guidance published in August 2015, the National Institute for Health and Care Excellence (NICE) advised that vedolizumab is the recommended treatment for adults with moderate to severe Crohn\u2019s disease if a type of treatment called a tumour necrosis factor alpha inhibitor is not suitable or has not worked well enough. NICE also recommend vedolizumab as a possible treatment for adults with moderate to severe ulcerative colitis in separate guidance published on 5 June 2015.<\/p> In both cases, people should be able to have vedolizumab until it stops working, or surgery is needed, or for 12 months after starting it, whichever is shorter. Their condition should be assessed 12 months after they started taking vedolizumab. If they still have symptoms but it is clear that the treatment is helping, they can continue to have the drug. If they no longer have symptoms, treatment can be stopped, and later restarted if their symptoms return. Drugs recommended by NICE should be available on the NHS within three months of the technology appraisal guidance being issued.<\/p> NICE has set out best practice in the diagnosis, treatment care and support of patients with Crohn\u2019s diseases and ulcerative colitis in its guidance Crohn\u2019s Disease Management in Adults, Children and Young People<\/em> in October 2012, and Ulcerative Colitis<\/em> Management in Adults, Children and Young People<\/em> , published in June 2013. Treatment for both Crohn\u2019s disease and ulcerative colitis is largely directed at symptom relief to improve quality of life, rather than cure. Management options include drug therapy, dietary and lifestyle advice and, in severe or chronic active disease, surgery.<\/p> The National Institute for Health and Care Excellence (NICE) is the independent body which makes decisions on the clinical and cost effectiveness of products based on a thorough assessment of the best available evidence and in consultation with stakeholders. National Health Service commissioners are required to fund drugs and treatments recommended by NICE technology appraisals.<\/p> Bendamustine (Levact) is recommended by NICE as a possible treatment for some people with chronic lymphocytic leukaemia of Binet stage B or C.<\/p> NICE is currently appraising ibrutinib (Imbruvica) for the treatment of (i) chronic lymphocytic leukaemia (NICE\u2019s final guidance is expected in June 2016) and (ii) mantle cell, relapsed, refractory lymphoma (NICE\u2019s final guidance is expected in December 2016).<\/p> The Accelerated Access Review, chaired by Sir Hugh Taylor, will make recommendations to government on reforms to accelerate access for National Health Service patients to innovative medicines and medical technologies (including devices, diagnostics and digital), making our country the best place in the world to design, develop and deploy these products. This will cover products that may already be on the market and off patent but are being innovatively repurposed to treat conditions other than those in remit of the existing license.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2015-10-27", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2015-10-27T15:50:14.473Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-10-22", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Drugs: Licensing"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, whether addressing barriers to licensing off-patent, repurposed drugs in an aim of the current Accelerated Access Review.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/253", "label" : {"_value" : "Biography information for Mr Laurence Robertson"}
}
, "tablingMemberConstituency" : {"_value" : "Tewkesbury"}
, "tablingMemberPrinted" : [{"_value" : "Mr Laurence Robertson"}
], "uin" : "13134"}
, {"_about" : "http://data.parliament.uk/resources/423349", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/423349/answer", "answerText" : {"_value" : " The Government hosted a Roundtable Event to explore the issues around off-label prescribing as part of its response to a Private Member\u2019s Bill presented in the last Parliament. The Government\u2019s position on the current Off Patent Drugs Bill and how that relates to issues identified at the Roundtable Event will be shared at the Bill\u2019s second reading on 6 November 2015.<\/p> <\/strong><\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2015-10-27", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2015-10-27T15:51:52.64Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-10-22", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Breast Cancer"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, pursuant to the Answer of 21 October 2015 to Question 12247, on breast cancer, what assessment his Department has made of the 26 recommendations produced by charities on access to off-patent, repurposed drugs following the roundtable event of February 2015.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/253", "label" : {"_value" : "Biography information for Mr Laurence Robertson"}
}
, "tablingMemberConstituency" : {"_value" : "Tewkesbury"}
, "tablingMemberPrinted" : [{"_value" : "Mr Laurence Robertson"}
], "uin" : "13077"}
, {"_about" : "http://data.parliament.uk/resources/423360", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/423360/answer", "answerText" : {"_value" : " Where there is a clinical need to do so for a patient, clinicians are legally able to prescribe bisphosphonates for breast cancer prevention.<\/p> NHS England\u2019s Breast Cancer Clinical Reference Group (CRG) has included the use of bisphosphonates in their draft service guidance for breast cancer. The CRG has highlighted bisphosphonates as a key issue for potential improvement in survival outcomes.<\/p> NHS England expects the draft service guidance to be finalised and available for dissemination in the autumn of 2015. It will then be up to clinical commissioning groups to consider how they adopt this in to their local commissioning activities.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2015-10-27", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2015-10-27T15:51:16.727Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-10-22", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Breast Cancer: Drugs"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what steps he has taken to make bisphosphonates routinely available on the NHS to prevent the spread of breast cancer to bones.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/253", "label" : {"_value" : "Biography information for Mr Laurence Robertson"}
}
, "tablingMemberConstituency" : {"_value" : "Tewkesbury"}
, "tablingMemberPrinted" : [{"_value" : "Mr Laurence Robertson"}
], "uin" : "12952"}
, {"_about" : "http://data.parliament.uk/resources/422970", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/422970/answer", "answerText" : {"_value" : " The information requested is provided in the following table:<\/p> <\/strong><\/p> Pathfinder clinical commissioning groups.<\/p><\/td> GP Practices<\/p><\/td><\/tr> Blackburn with Darwen<\/p><\/td> 23<\/p><\/td><\/tr> Leeds<\/p><\/td> 15<\/p><\/td><\/tr> West Hampshire<\/p><\/td> 30<\/p><\/td><\/tr> Somerset<\/p><\/td> 56<\/p><\/td><\/tr><\/tbody><\/table> <\/strong><\/p> <\/strong><\/p> <\/strong><\/p> <\/strong><\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2015-10-29", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2015-10-29T17:11:25.373Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-10-21", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "General Practitioners: Databases"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, pursuant to the Answer of 23 July 2015 to Question 7630, how many GP practices in each pathfinder area have signed up to care.data to date in total.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1503", "label" : {"_value" : "Biography information for Mr Jamie Reed"}
}
, "tablingMemberConstituency" : {"_value" : "Copeland"}
, "tablingMemberPrinted" : [{"_value" : "Mr Jamie Reed"}
], "uin" : "12767"}
], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=1&answeringDeptId=17&answer.answeringMemberPrinted=George+Freeman&max-answer.dateOfAnswer=2015-10-29&max-answer.questionFirstAnswered.=2018-11-12T15%3A35%3A43.347Z", "page" : 0, "startIndex" : 1, "totalResults" : 917, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}
"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2015-10-29", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "13299"}
, {"_value" : "13300"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2015-10-29T17:23:06.45Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-10-26", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Crohn's Disease"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what progress has been made on tackling Crohn's disease.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4519", "label" : {"_value" : "Biography information for James Cartlidge"}
}
, "tablingMemberConstituency" : {"_value" : "South Suffolk"}
, "tablingMemberPrinted" : [{"_value" : "James Cartlidge"}
], "uin" : "13375"}
, {"_about" : "http://data.parliament.uk/resources/423943", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/423943/answer", "answerText" : {"_value" : "
"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2015-10-29", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "13300"}
, {"_value" : "13375"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2015-10-29T17:23:06.353Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-10-26", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Inflammatory Bowel Disease: Drugs"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what estimate his Department has made of the number of people with both ulcerative colitis and Crohn's disease who have benefitted from the use of vedolizumab as a treatment option since February 2015; and what the cost of this treatment has been in that period.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/3939", "label" : {"_value" : "Biography information for Andrew Percy"}
}
, "tablingMemberConstituency" : {"_value" : "Brigg and Goole"}
, "tablingMemberPrinted" : [{"_value" : "Andrew Percy"}
], "uin" : "13299"}
, {"_about" : "http://data.parliament.uk/resources/423944", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/423944/answer", "answerText" : {"_value" : "
"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2015-10-29", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "13299"}
, {"_value" : "13375"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2015-10-29T17:23:06.403Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-10-26", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Crohn's Disease: Drugs"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what recent assessment his Department has made of the effectiveness of vedolizumab as a treatment for Crohn's disease.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/3939", "label" : {"_value" : "Biography information for Andrew Percy"}
}
, "tablingMemberConstituency" : {"_value" : "Brigg and Goole"}
, "tablingMemberPrinted" : [{"_value" : "Andrew Percy"}
], "uin" : "13300"}
, {"_about" : "http://data.parliament.uk/resources/423952", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/423952/answer", "answerText" : {"_value" : "
"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2015-10-29", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2015-10-29T17:31:39.653Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-10-26", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cancer: Drugs"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what recent assessment he has made of the effectiveness of the (a) Bendamustine and (b) Ibrutinib drugs in treating cancer; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/253", "label" : {"_value" : "Biography information for Mr Laurence Robertson"}
}
, "tablingMemberConstituency" : {"_value" : "Tewkesbury"}
, "tablingMemberPrinted" : [{"_value" : "Mr Laurence Robertson"}
], "uin" : "13444"}
, {"_about" : "http://data.parliament.uk/resources/423341", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/423341/answer", "answerText" : {"_value" : "